Navigation Links
Biodel to Report First Quarter Fiscal Year 2012 Financial Results on February 8, 2012
Date:2/3/2012

DANBURY, Conn., Feb. 3, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will issue its first quarter fiscal year 2012 financial results on February 8, 2012.  Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress. 

February 8, 2012 schedule: 

 4:00 pm EST:

1Q fiscal year 2012 results will be distributed 

 4:15 pm EST:

Conference call participants should dial: 

+1 ( 877 ) 303 - 8028  (United States) or 

+1 ( 760 ) 536 - 5167  (International) 

  

 4:30 pm EST:

Conference call begins 

  

 Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at www.biodel.com.  The audio webcast will be archived and available for replay through the website.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients.  We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.  For further information regarding Biodel, please visit the company's website at www.biodel.com.

BIOD-G

Contact: Seth D. Lewis, +1-646-378-2952

 

 


'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biodel Announces Name Change for Lead Product Candidate
2. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
3. Biodel to Raise $30 Million Through Registered Direct Offering
4. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
5. Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
6. BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
7. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
8. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
9. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
10. Par Pharmaceutical Reports Second Quarter 2008 Results
11. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time ... US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. ... US2020. , US2020’s mission is to change the trajectory of STEM education in ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
Breaking Biology News(10 mins):